Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence

Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.

Medicare Part B contractor Palmetto GBA’s molecular diagnostic reimbursement initiative, known as MolDx, is being watched closely as a possible stepping stone to broader Medicare adoption of more rigorous evidence requirements for molecular diagnostics, including companion diagnostics.

MolDx requires for the first time that labs submit tech assessments for each test to allow Palmetto to establish coverage policies on an assay-by-assay basis. The new tech assessment standards...

More from Archive

More from Medtech Insight